Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohammed Ullah

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Molecular Pharmaceutics|December 23, 2009
Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studiesJack A Cook, Bo Feng, Katherine S Fenner, et al.
Pharmacology Research & Perspectives|December 7, 2018
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organsAgnès Poirier, Marla Weetall, Katja Heinig, et al.
Neuro-Oncology|May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoproteinHolger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 8, 2021
Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the <i>SMN2</i> mRNA Splicing Modifier RisdiplamStephen Fowler, Andreas Brink, Yumi Cleary, et al.
Investigational New Drugs|August 21, 2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)Georgina Meneses-Lorente, Stephen Fowler, Elena Guerini, et al.
Mabs|April 26, 2017
Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanismsClaudia A Castro Jaramillo, Sara Belli, Anne-Christine Cascais, et al.
Heliyon|November 30, 2020
Epidemiological study of human rabies cases in Bangladesh through verbal autopsyMd Sohel Rana, Umme Ruman Siddiqi, Sumon Ghosh, et al.
Brain : a Journal of Neurology|June 24, 2020
A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelinationTuancheng Feng, Rory R Sheng, Santiago Solé-Domènech, et al.
Clinical Pharmacology and Therapeutics|October 20, 2019
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and RecommendationsKunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 18, 2018
Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus InhibitorNicole A Kratochwil, Miriam Triyatni, Martina B Mueller, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Molecular Pharmaceutics|December 23, 2009
Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studiesJack A Cook, Bo Feng, Katherine S Fenner, et al.
Pharmacology Research & Perspectives|December 7, 2018
Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organsAgnès Poirier, Marla Weetall, Katja Heinig, et al.
Neuro-Oncology|May 9, 2020
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoproteinHolger Fischer, Mohammed Ullah, Cecile C de la Cruz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 8, 2021
Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the <i>SMN2</i> mRNA Splicing Modifier RisdiplamStephen Fowler, Andreas Brink, Yumi Cleary, et al.
Investigational New Drugs|August 21, 2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)Georgina Meneses-Lorente, Stephen Fowler, Elena Guerini, et al.
Mabs|April 26, 2017
Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanismsClaudia A Castro Jaramillo, Sara Belli, Anne-Christine Cascais, et al.
Heliyon|November 30, 2020
Epidemiological study of human rabies cases in Bangladesh through verbal autopsyMd Sohel Rana, Umme Ruman Siddiqi, Sumon Ghosh, et al.
Brain : a Journal of Neurology|June 24, 2020
A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelinationTuancheng Feng, Rory R Sheng, Santiago Solé-Domènech, et al.
Clinical Pharmacology and Therapeutics|October 20, 2019
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and RecommendationsKunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 18, 2018
Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus InhibitorNicole A Kratochwil, Miriam Triyatni, Martina B Mueller, et al.
Pageof 4